Mirati Therapeutics, Inc. (MRTX) Upgraded by ValuEngine to Hold

ValuEngine upgraded shares of Mirati Therapeutics, Inc. (NASDAQ:MRTX) from a sell rating to a hold rating in a research report released on Thursday.

A number of other brokerages have also issued reports on MRTX. Oppenheimer Holdings, Inc. started coverage on shares of Mirati Therapeutics in a research note on Monday, September 18th. They set an outperform rating and a $18.00 target price for the company. Zacks Investment Research downgraded Mirati Therapeutics from a hold rating to a sell rating in a report on Thursday, October 5th. SunTrust Banks, Inc. restated a buy rating and issued a $13.00 price objective on shares of Mirati Therapeutics in a report on Monday, October 2nd. CIBC started coverage on Mirati Therapeutics in a report on Tuesday, September 19th. They issued an outperform rating and a $18.00 price objective for the company. Finally, Leerink Swann lifted their price objective on Mirati Therapeutics from $7.00 to $9.00 and gave the company a market perform rating in a report on Friday, September 15th. Four equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. The stock presently has an average rating of Buy and an average price target of $13.71.

Mirati Therapeutics (MRTX) traded down $1.75 during midday trading on Thursday, reaching $17.25. 912,635 shares of the company’s stock traded hands, compared to its average volume of 553,318. Mirati Therapeutics has a 52 week low of $2.70 and a 52 week high of $19.25.

Mirati Therapeutics (NASDAQ:MRTX) last posted its quarterly earnings data on Wednesday, November 1st. The biotechnology company reported ($0.65) EPS for the quarter, topping the consensus estimate of ($0.81) by $0.16. equities analysts anticipate that Mirati Therapeutics will post -2.87 EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This piece of content was first posted by Sports Perspectives and is the property of of Sports Perspectives. If you are viewing this piece of content on another website, it was copied illegally and reposted in violation of U.S. and international trademark & copyright law. The correct version of this piece of content can be viewed at https://sportsperspectives.com/2017/11/17/mirati-therapeutics-inc-mrtx-upgraded-by-valuengine-to-hold.html.

In related news, major shareholder Venbio Select Advisor Llc acquired 650,000 shares of the business’s stock in a transaction dated Thursday, November 16th. The shares were purchased at an average price of $13.00 per share, for a total transaction of $8,450,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Jamie Christensen sold 7,499 shares of the company’s stock in a transaction dated Thursday, November 2nd. The shares were sold at an average price of $14.00, for a total transaction of $104,986.00. Following the transaction, the senior vice president now owns 10,169 shares in the company, valued at approximately $142,366. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 22,544 shares of company stock worth $355,176. Corporate insiders own 5.10% of the company’s stock.

Institutional investors and hedge funds have recently bought and sold shares of the company. KCG Holdings Inc. purchased a new stake in Mirati Therapeutics in the first quarter valued at approximately $106,000. Susquehanna International Group LLP boosted its position in Mirati Therapeutics by 46.5% in the second quarter. Susquehanna International Group LLP now owns 50,509 shares of the biotechnology company’s stock valued at $184,000 after buying an additional 16,030 shares during the last quarter. PDT Partners LLC purchased a new stake in Mirati Therapeutics in the second quarter valued at approximately $200,000. LMR Partners LLP purchased a new stake in Mirati Therapeutics in the second quarter valued at approximately $236,000. Finally, Citadel Advisors LLC purchased a new stake in Mirati Therapeutics in the third quarter valued at approximately $268,000. Hedge funds and other institutional investors own 59.49% of the company’s stock.

About Mirati Therapeutics

Mirati Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of oncology products. The company’s clinical stage product candidates include glesatinib, an orally-bioavailable, potent, small molecule kinase inhibitor that is in Phase II clinical trials for the treatment of non-small cell lung cancer (NSCLC) patients with genetic alterations of MET; and in Phase Ib clinical trials in patients with genetic alterations of MET and Axl in NSCLC and other solid tumors.

Analyst Recommendations for Mirati Therapeutics (NASDAQ:MRTX)

Receive News & Ratings for Mirati Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirati Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply